1. Academic Validation
  2. A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells

A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells

  • EMBO Mol Med. 2019 Oct;11(10):e9930. doi: 10.15252/emmm.201809930.
Abir Arfaoui 1 2 3 Claire Rioualen 4 Violette Azzoni 1 Guillaume Pinna 5 Pascal Finetti 6 Julien Wicinski 1 Emmanuelle Josselin 7 Manon Macario 1 Rémy Castellano 7 Candi Léonard-Stumpf 1 Anthony Bal 1 Abigaelle Gros 1 Sylvain Lossy 5 Maher Kharrat 2 Yves Collette 7 Francois Bertucci 6 Daniel Birnbaum 6 Hayet Douik 2 3 Ghislain Bidaut 4 Emmanuelle Charafe-Jauffret 1 Christophe Ginestier 1
Affiliations

Affiliations

  • 1 Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Epithelial Stem Cells and Cancer Lab, Aix-Marseille Univ, Marseille, France.
  • 2 Faculté de Médecine de Tunis, LR99ES10 Laboratoire de Génétique Humaine, Université de Tunis El Manar, Tunis, Tunisia.
  • 3 Service de Biologie Clinique, Institut Salah Azaiz, Tunis, Tunisia.
  • 4 Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Plateform Integrative Bioinformatics, Cibi, Aix-Marseille Univ, Marseille, France.
  • 5 Plateforme ARN Interférence, Service de Biologie Intégrative et de Génétique Moléculaire (SBIGeM), I2BC, CEA, CNRS, Université Paris-Saclay, Gif-sur-Yvette, France.
  • 6 Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Molecular Oncology "Equipe labellisée Ligue Contre le Cancer", Aix-Marseille Univ, Marseille, France.
  • 7 Inserm, CNRS, Institut Paoli-Calmettes, CRCM, TrGET Plateform, Aix-Marseille Univ, Marseille, France.
Abstract

Therapeutic resistance is a major clinical challenge in oncology. Evidence identifies Cancer Stem Cells (CSCs) as a driver of tumor evolution. Accordingly, the key stemness property unique to CSCs may represent a reservoir of therapeutic target to improve Cancer treatment. Here, we carried out a genome-wide RNA interference screen to identify genes that regulate breast CSCs-fate (bCSC). Using an interactome/regulome analysis, we integrated screen results in a functional mapping of the CSC-related processes. This network analysis uncovered potential therapeutic targets controlling bCSC-fate. We tested a panel of 15 compounds targeting these regulators. We showed that mifepristone, salinomycin, and JQ1 represent the best anti-bCSC activity. A combination assay revealed a synergistic interaction of salinomycin/JQ1 association to deplete the bCSC population. Treatment of primary breast Cancer xenografts with this combination reduced the tumor-initiating cell population and limited metastatic development. The clinical relevance of our findings was reinforced by an association between the expression of the bCSC-related networks and patient prognosis. Targeting bCSCs with salinomycin/JQ1 combination provides the basis for a new therapeutic approach in the treatment of breast Cancer.

Keywords

JQ1; RNAi screen; breast cancer; cancer stem cells; salinomycin.

Figures
Products